Roivant Sciences
| File:Roivantlogo.png | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2014 |
| Founder | Vivek Ramaswamy |
| Headquarters | |
| Website | www |
Roivant Sciences, Ltd. is a global biopharmaceutical company that focuses on helping patients by bringing new medicinations to market, through clinical development. Roivant uses mechanisms such as acquisitions, strategic alliances, collaborations and partnerships to accelerate the process.[1][2] The global company was founded in May 2014 by Vivek Ramaswamy and Lawrence Friedhoff[2][3][4] and is headquartered in Bermuda with offices and research facilities in New York City, Durham, NC and Switzerland.
The businesses under the Roivant parent organization are arranged by therapeutic area, and include Axovant, Myovant, Enzyvant and Dermavant.[2] Axovant is developing therapies for neurological diseases, including intepirdine for Alzheimer’s disease and Lewy body dementia.[3] Myovant, formed as a spin-out of the women’s health and prostate cancer programs of Takeda Pharmaceuticals, is working to develop therapies for uterine fibroids, endometriosis, and prostate cancer.[5][6][7] Myovant has a worldwide license for the drug Relugolix.[8] Enzyvant is working to develop therapies for rare diseases, including Farber disease.[9][10][11][12]
Axovant’s IPO was the largest biotech IPO in American history, raising $360 million.[1][3][13]
References
- ^ a b Vardi, Nathan. "Billionaire Andreas Halvorsen's Hedge Fund Backs Private Biotech Roivant Sciences". Forbes. Retrieved 2016-10-07.
- ^ a b c Vardi, Nathan. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 2016-10-07.
- ^ a b c Pollack, Andrew (2015-06-11). "Shares of Axovant, Alzheimer's Drug Developer, Surge on Trading Debut". The New York Times. ISSN 0362-4331. Retrieved 2016-10-07.
- ^ "Biotechnology Company Overview of Axovant Sciences Ltd". Bloomberg. Retrieved 2016-10-25.
- ^ "NASDAQ | SEC Filing". secfilings.nasdaq.com. Retrieved 2016-10-07.
- ^ Clifford, Rebecca. "Takeda forms new women's health and cancer company". PMLIVE. Retrieved 2016-10-24.
- ^ Taylor, Nick Paul. "Axovant founder, Takeda install ex-Medivation CMO at helm of PhIII-ready startup". Fierce Biotech. Retrieved 2016-10-07.
- ^ Boggs, Jennifer. "Roivant's Myovant Sciences files for $173M IPO to fund its phase III-ready asset". BioWorld. Retrieved 2016-10-07.
- ^ White, Victoria. "New company Enzyvant takes aim at Farber disease". Drug Target Review. Retrieved 2016-10-07.
- ^ Adams, Ben. "Roivant and Plexcera launch rare disease focused spinout". Fierce Biotech. Retrieved 2016-10-07.
- ^ Black, Andrew. "Enzyvant Sciences Created to Focus on Treatment of Farber Disease". Rare Disease Report. Retrieved 2016-10-07.
- ^ "New Developments in Farber Disease Research". Lysosomal Disease Network. Retrieved 2016-10-11.
- ^ "Axovant Sciences Ltd". United States Securities and Exchange Commission. Retrieved 2016-10-24.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |